

Prasad Devarajan, M.D.

Louise M. Williams Endowed Chair, Professor of Pediatrics and Developmental Biology and Director of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center

Dr. Prasad Devarajan is the Louise M. Williams Endowed Chair and professor of pediatrics and developmental biology at the Cincinnati Children's Hospital Medical Center. He is also director of nephrology and hypertension.

In 2005, Dr. Devarajan was recognized as one of the "2005 Best Doctors." He serves as a reviewer for *The Lancet*, *Journal of Cell Biology*, *Journal of Biological Chemistry*, *Frontiers in Bioscience*, *Quarterly Reviews in Biology*, *American Journal of Physiology*, *Journal of American Society of Nephrology*, *Pediatric Nephrology*, *Kidney International*, *Laboratory Investigation*, *Journal of Urology* and *Journal of Hormone and Metabolic Research*. In addition, he is an abstract reviewer for the American Society of Nephrology and Society for Pediatric Research as well as an external and ad hoc reviewer for the National Institutes of Health (NIH) and National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK).

Currently, Dr. Devarajan is a member of the Council on Kidney in Cardiovascular Disease, American Society for Pediatric Nephrology Scientific Council and Eastern Society for Pediatric Research. Dr. Devarajan received both his premedical and M.D. degrees from Bombay University in India. He completed his graduate research, an internship and residency at State University of New York. Dr. Devarajan was a NIH Fellow, received a Postdoctoral Fellowship and served as a research assistant at Yale University School of Medicine. Later he taught as an assistant professor in Yale's Department of Pediatrics.

Dr. Devarajan continued his teaching career at Albert Einstein College of Medicine's Department of Pediatrics. He served as the director of research while earning the title of associate professor. In July 2002, Dr. Devarajan began his current position as the Williams Professor of Pediatrics and Developmental Biology and director of nephrology and hypertension at Cincinnati Children's Hospital Medical Center.

Dr. Devarajan has served as principal investigator on several NIH and NIDDK studies including, "Ankyrin: crucial linker in renal cell apoptotic cascades;" "Implications of the Ask1/JNK Pathway in ARF;" and "NGAL: A Novel Early Biomarker of Acute Renal Injury." He is currently working on "Mechanisms of Na, K-ATPase polarity in renal development." Through Cincinnati Children's Technology Validation Board Fund and Cincinnati Children's Translational Research Initiative he has produced research entitled, "A sensitive non-invasive method of detecting early sub-clinical renal injury" and "A novel biomarker for early detection of renal injury" respectively. Over the past two years, he served as the principal investigator for the American Heart Association's study on "A novel biomarker for early ischemic renal injury."

Dr. Devarajan's recent publications include "Neutrophil Gelatinase-Associated Lipocalin (NGAL): A novel urinary biomarker for cisplatin nephrotoxicity" in the *American Journal of Nephrology*, "Amelioration of ischemic acute renal injury by NGAL" in the *Journal of the American Society of Nephrology* and "Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury following cardiac surgery" in *The Lancet*.